Results 41 to 50 of about 335,095 (291)

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching [PDF]

open access: yes, 2020
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses, it is common that patients allocated to the control group switch
Bore, Alexander   +3 more
core   +2 more sources

Estimation of treatment effects in weighted log-rank tests

open access: yesContemporary Clinical Trials Communications, 2017
Non-proportional hazards have been observed in clinical trials. The log-rank test loses power and the standard Cox model generally produces biased estimates under such conditions.
Ray S. Lin, Larry F. León
doaj   +1 more source

Which test for crossing survival curves? A user’s guideline

open access: yesBMC Medical Research Methodology, 2022
Background The exchange of knowledge between statisticians developing new methodology and clinicians, reviewers or authors applying them is fundamental. This is specifically true for clinical trials with time-to-event endpoints.
Ina Dormuth   +5 more
doaj   +1 more source

An exact corrected log-likelihood function for Cox's proportional hazards model under measurement error and some extensions [PDF]

open access: yes, 2002
This paper studies Cox`s proportional hazards model under covariate measurement error. Nakamura`s (1990) methodology of corrected log-likelihood will be applied to the so called Breslow likelihood, which is, in the absence of measurement error ...
Augustin, Thomas
core   +1 more source

Treating non-responders: pitfalls and implications for cancer immunotherapy trial design

open access: yesJournal of Hematology & Oncology, 2020
Background Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment.
Zhenzhen Xu   +3 more
doaj   +1 more source

Partially linear censored quantile regression [PDF]

open access: yes, 2009
Censored regression quantile (CRQ) methods provide a powerful and flexible approach to the analysis of censored survival data when standard linear models are felt to be appropriate.
B Honore   +17 more
core   +1 more source

Effect of surgical treatment on patients with stage T3 or T4 triple-negative breast cancer: a SEER-based retrospective observational study

open access: yesFrontiers in Endocrinology, 2023
BackgroundThe use of surgery is controversial in patients with stage T3 or T4 triple-negative breast cancer (TNBC). We aimed to explore the effect of surgical treatment on overall survival (OS) of these patients.MethodsA total of 2,041 patients were ...
Jie Hu   +12 more
doaj   +1 more source

A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects

open access: yesContemporary Clinical Trials Communications, 2015
The semi-parametric proportional hazards model is widely adopted in randomized clinical trials with time-to-event outcomes, and the log-rank test is frequently used to detect a potential treatment effect.
Pei He, Zheng Su
doaj   +1 more source

Nonlinear relationship between atherogenic index of plasma and the risk of prediabetes: a retrospective study based on Chinese adults

open access: yesCardiovascular Diabetology, 2023
Background The atherogenic index of plasma (AIP) can reflect the burden of atherosclerosis. Hyperglycemia is one of the leading causes of atherosclerosis. However, the relationship between AIP and prediabetes is rarely studied.
Xiaodan Zheng   +4 more
doaj   +1 more source

Mathematical methods and models for radiation carcinogenesis studies [PDF]

open access: yes, 1986
Research on radiation carcinogenesis requires a twofold approach. Studies of primary molecular lesions and subsequent cytogenetic changes are essential, but they cannot at present provide numerical estimates of the risk of small doses of ionizing ...
A.M. Kellerer   +25 more
core   +1 more source

Home - About - Disclaimer - Privacy